ErlichKSMillsJChatisPMertzGJBuschDFFollansbeeSE. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med1989; 320: 293–6.
2.
CrumpackerCSSchnipperLEMarloweSIKowalskyPNHersheyBJLevinMJ. Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med1982; 306: 343–6.
3.
NorrisSAKesslerHAFifeKH. Severe, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS. J Infect Dis1988; 157: 209–10.
4.
SchinaziRFdel BeneVScottRTDudley-ThorpeJB. Characterization of acyclovir-resistant and -sensitive herpes simplex virus isolated from a patient with an acquired immune deficiency. J Antimicrob Chemother1986; 18 (suppl B): 127–34.
5.
SnoeckRAndreiGGerardMSilvermanAHeddermanABalzariniJ. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes infection with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC). Clin Infect Dis1994; 18: 570–8.
6.
ReusserP. Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. J Hosp Infect1996; 33: 235–48.
7.
AbghariSZStultingRD. Zhu Z, Schinazi RF, Kaufman HE. Effect of genetically determined host factors on the efficacy of vidarabine, acyclovir and 5-trifluorothymidine in herpes simplex virus type I infection. Ophthalmic Res1994; 26: 95–104.
8.
LalezariJPDrewWLGlutzerEMinerDSafrinSOwenWFJr. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis1994; 170: 570–2.
9.
SafrinSCrumpackerCChatisPDavisRHafnerRRushJ. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med1991; 325: 551–5.
10.
BurdgeDRChowAWSacksSL. Neurotoxic effects during vidarabine therapy for herpes zoster. Can Med Assoc J1985; 132: 392–5.
11.
NadelAM. Vidarabine therapy for herpes simplex encepthalitis: the development of an unusual tremor during treatment. Arch Neurol1981; 38: 384–5.
12.
AminARRobinsonMRSmithDDSwensonCFLuqueAE. Trifluorothymidine 0.5% ointment in the treatment of aciclovir-resistant mucocutaneous herpes simplex in AIDS. AIDS1996; 10: 1051–3.
13.
BalfourHHJrBensonCBraunJCassensBEriceAFriedman-KleinA. Management of acyclovir-resistant herpes simplex and varicellazoster virus infections. J Acquir Immune Defic Syndr1994; 7: 254–60.
14.
BischofbergerNHitchcockMJChenMSBarkhimerDBCundyKCKentKM. 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother1994; 38: 2387–91.
15.
MaudgalPCDe ClercqE. (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis. Invest Ophthalmol Vis Sci1991; 32: 1816–20.
16.
PalmerJVogtPEKernER. Prevention and treatment of experimental genital herpes simplex virus type II (HSV-2) infections with topical HPMPC (abstract 205). Antiviral Res1995; 26: A334.
17.
De ClercqEHolyA. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice. Antimicrob Agents Chemother1991; 35: 701–6.
18.
StanberryLR. Pathogenesis of herpes simplex virus infections and animal models for its study. Curr Top Microbiol Immunol1992; 179: 15–30.
19.
JayasuriyaAKNashAA. Pathogenesis and immunobiology of herpes simplex virus in mouse and man. Cancer Invest1985; 3: 199–207.
20.
KleinRJ. Initiation and maintenance of latent herpes simplex virus infections: the paradox of perpetual immobility and continuous movement. Rev Infect Dis1985; 7: 21–30.
21.
AlrabiahFASacksSL. New antiherpesvirus agents: their targets and therapeutic potential. Drugs1996; 52: 17–32.
22.
LalezariJSchackerTFeinbergJLeeSGatheJKramerF. A randomized, double-blinded, placebo-controlled study of cidofovir topical gel for acyclovir-resistant herpes simplex virus infections in patients with AIDS (abstract 184). In: Program and Abstracts of the 3rd Conference on Retroviruses and Oppurtunistic Infections, Washington, DC, January 28–February 2, 1996.
23.
LalezariJSchackerTFeinbergJGatheJLeeSCheungT. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex infection in patients with AIDS. J Infect Dis1997; 176: 892–8.
24.
EnglundJAZimmermanMESwierkoszEMGoodmanJLSchollDRBalfourHHJr. Herpes simplex virus resistant to acyclovir: a study in a tertiary care center. Ann Intern Med1990; 112: 416–22.
